ArticleEuropean journal of immunology2011
Subsets of human CD4(+) regulatory T cells express the peripheral homing receptor CXCR3.
Article in European journal of immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00023231 (Calcineurin Inhibitor Sparing Protocol in Living Donor Pediatric Kidney Transplantation), which is not on this map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Calcineurin Inhibitor Sparing Protocol in Living Donor Pediatric Kidney Transplantation
Who cites it
42 citing papers in PubMed, 68 citations in OpenAlex.
- Transcriptional and phenotypic alterations of regulatory and effector T cells in type 1 diabetes mellitus.Molecular biomedicine · 2026Article
- Article
- Regulatory T cell and endothelial cell crosstalk.Nature reviews. Immunology · 2025Review
- Beyond Adaptive Immunity: Trained Innate Immune Responses as a Novel Frontier in Hepatocellular Carcinoma Therapy.Cancers · 2025Review
- Immunomodulation by allograft endothelial cells.Frontiers in transplantation · 2025Review
- Lactylation-driven TNFR2 expression in regulatory T cells promotes the progression of malignant pleural effusion.Journal for immunotherapy of cancer · 2024Article
- Phenotypic profiling of human induced regulatory T cells at early differentiation: insights into distinct immunosuppressive potential.Cellular and molecular life sciences : CMLS · 2024Article
- The Role of Chemokines in Orchestrating the Immune Response to Pancreatic Ductal Adenocarcinoma.Cancers · 2024Review
- Tregs levels and phenotype modifications during Amyotrophic Lateral Sclerosis course.Frontiers in immunology · 2024Article
- Multimodal immune cell phenotyping in GI biopsies reveals microbiome-related T cell modulations in human GvHD.Cell reports. Medicine · 2023Article
- TCF-1 negatively regulates the suppressive ability of canonical and noncanonical Tregs.Journal of leukocyte biology · 2023Article
- CD4Frontiers in immunology · 2022Review
- An integrated cytokine and kynurenine network as the basis of neuroimmune communication.Frontiers in neuroscience · 2022Review
- CXCR4 blockade reduces the severity of murine heart allograft rejection by plasmacytoid dendritic cell-mediated immune regulation.Scientific reports · 2021Article
- Interleukin-2-inducible T-cell kinase (Itk) signaling regulates potent noncanonical regulatory T cells.Clinical and translational medicine · 2021Article
- Harnessing biomaterials for lymphatic system modulation.Acta biomaterialia · 2021Review
- Review
- Antigen-Specific Regulatory T Cell Therapy in Autoimmune Diseases and Transplantation.Frontiers in immunology · 2021Review
- BCG vaccination reduces the mortality of Mycobacterium tuberculosis-infected type 2 diabetes mellitus mice.JCI insight · 2020Article
- FTY720 Suppresses Liver Tumor Growth and Metastasis by Reducing Circulating Regulating T Cells and Enhancing the Anti-Tumor Effect of Rapamycin.OncoTargets and therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
Abstract
Regulatory T cells (Tregs) migrate into peripheral sites of inflammation such as allografts undergoing rejection, where they serve to suppress the immune response. In this study, we find that ∼30-40% of human CD25(hi) FOXP3(+) CD4(+) Tregs express the peripheral CXC chemokine receptor 3 (CXCR3) and that this subset has potent immunoregulatory properties. Consistently, we observed that proliferative responses as well as IFN-γ production were significantly higher using CXCR3-depleted versus undepleted responders in the mixed lymphocyte reaction, as well as following mitogen-dependent activation of T cells. Using microfluidics, we also found that CXCR3 was functional on CXCR3(pos) Tregs, in as much as chemotaxis and directional persistence towards interferon-γ-inducible protein of 10 kDa (IP-10) was significantly greater for CXCR3(pos) than CXCR3(neg) Tregs. Following activation, CXCR3-expressing CD4(+) Tregs were maintained in vitro in cell culture in the presence of the mammalian target of rapamycin (mTOR) inhibitor rapamycin, and we detected higher numbers of circulating CXCR3(+) FOXP3(+) T cells in adult and pediatric recipients of renal transplants who were treated with mTOR-inhibitor immunosuppressive therapy. Collectively, these results demonstrate that the peripheral homing receptor CXCR3 is expressed on subset(s) of circulating human Tregs and suggest a role for CXCR3 in their recruitment into peripheral sites of inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.